Navigation Links
New analysis helps guide use of erlotinib in advanced non-small cell lung cancer
Date:4/18/2012

Lugano-CH/Aurora-US-CO/Geneva-CH, 18 April 2012 -- Patients with advanced non-small cell lung cancer should only receive treatment with the drug erlotinib before receiving standard chemotherapy if their tumor is known to harbor EGFR mutations, researchers report at the 3rd European Lung Cancer Conference in Geneva, Switzerland.

The results of biomarker analyses of a recently reported clinical trial confirm that patients with unknown or negative mutation status should be treated with the standard chemotherapy first, they say.

The TORCH trial was a randomized phase III trial conducted in Italy and Canada, which compared the efficacy of treatment with erlotinib, followed at progression of disease by cisplatin and gemcitabine, against the standard reverse sequence. Erlotinib is a drug that specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase.

The primary endpoint of the original TORCH study was overall survival and 900 patients were planned, however the study was stopped early as the first interim analysis showed that the erlotinib-first regimen was inferior to the standard approach.

In the new study, Dr Ming Tsao and colleagues conducted an exploratory analysis on the TORCH patient tumor samples that were available for analysis, looking for molecular biomarkers known to be potential predictors of benefit from EGFR inhibitors.

"Our results show a significant interaction in progression-free survival favoring treatment with erlotinib first in EGFR-mutated patients, and favouring first treatment with chemotherapy in EGFR wild type [non-mutated] patients," said Dr Tsao, from the Princess Margaret Hospital.

"However there was no significant interaction between treatment efficacy and overall survival. This shows that using erlotinib to treat patients with a mutated tumor is always effective, both in first and in second line; of course, it is much more convenient for these patients to receive it as first line, as shown also in other trials," Dr Tsao said.

Patients with EGFR mutations benefit from the erlotinib-first regimen because their tumors are very sensitive to the anti-tumor activity of the drug, he explained.

"The take-home message from this study is that in advanced non-small cell lung cancer patients, treatment with erlotinib first should only be applied to patients whose tumor is known to harbor EGFR mutation," said Dr Tsao. "Patients with unknown or negative mutation status should be treated with the standard chemotherapy first."

Commenting on the study which he was not involved in, Dr Tetsuya Mitsudomi from Aichi Cancer Center Hospital in Nagoya, Japan, member of the IASLC Board of Directors, said: "Many previous trials, for instance IPASS, NEJ002, WJTOG3405, OPTIMAL, EUROTAC, have already shown that EGFR mutation is the most reliable predictive marker for EGFR-TKI treatment. The current paper was able to confirm the importance of EGFR mutation testing when considering the use of erlotinib, especially in consideration of the far shorter progression-free survival obtained with erlotinib when the mutation was absent. Consequently, although it was thought that erlotinib is active even in lung cancer patients without EGFR mutation if compared with gefitinib, this study suggests that erlotinib should be avoided when treating patients without EGFR mutation, at least in the first-line setting."

This biomarker analysis was preplanned but actually only 36% of the samples could be anlayzed for EGFR mutation. This relatively low tissue accrual rate is precedented by many clinical trials in which the mutation analysis was performed retrospectively. "Therefore, we also have to consider prospective determination of oncogene mutation when we want to raise this rate such as in NEJ, WJTOG, OPTIMAL and EUROTAC," Dr Mitsudomi added.

"In summary, the TORCH-BIO study adds imprortant evidence to the research field of EGFR-TKI in lung cancer and emphazizes the importance of biomarker study for improvement of clinical outcome."


'/>"/>

Contact: Vanessa Pavinato
media@esmo.org
European Society for Medical Oncology
Source:Eurekalert

Related biology news :

1. On the safe side: Contact-free analysis of chemical substances
2. Fine-scale analysis of the human brain yields insight into its distinctive composition
3. Buy coal? New analysis shows purchasing fossil fuel deposits best way to fight climate change
4. Analysis of stickleback genome sequence catches evolution in action
5. A new application allows online statistical analysis of gene-expression data
6. New analysis of premature infants heartbeats, breathing could be cues for leaving NICU
7. Beyond the microscope: Identifying specific cancers using molecular analysis
8. Analysis of generalized linear mixed models
9. Psychemedics Awarded Patent Fundamental To Hair Analysis Drug Testing
10. Sweeping genetic analysis of rare disease yields common mechanism of hypertension
11. Elusive ultrafine indoor air contaminants yield to NIST analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2020)... , ... July 09, 2020 , ... Today CJ BIO ... which will share insight on the “fifth taste” phenomenon that is revolutionizing ingredient mixes, ... Umami Advantage will be live on Monday, July 13, 2020 at11:00 AM (CDT) during ...
(Date:7/2/2020)... REDWOOD CITY, Calif. (PRWEB) , ... July 01, ... ... stage biotech company, presented its phase 1a findings of Neihulizumab, a biologic for ... annual conference in June 2020. Led by hemato-oncologist Dr. Paul J Martin of ...
(Date:7/1/2020)... ... July 01, 2020 , ... ... had completed the purchase of Teva-Takeda Pharmaceuticals’ packaging facility in Minakuchi, located in ... Japanese clinical supply facility located in Kakegawa, the new 60,000-square-foot facility will provide ...
Breaking Biology News(10 mins):
(Date:7/31/2020)... Ariz. (PRWEB) , ... July 29, 2020 , ... R3 ... joint injections for only $3950. With 50 million stem cells total, patients may choose ... stem cell therapy works for arthritic joints (BMC Musculoskelet Disord. 2016). At R3 International, ...
(Date:7/31/2020)... ... July 29, 2020 , ... eSource has long been touted as ... cover the history of eSource, the reasons it did not take off as quickly ... site source, the industry is moving towards capturing data electronically for clinical trials and ...
(Date:7/18/2020)... ... ... “We are thrilled to deliver this new technology to the industry” said Matt ... the market and we were pleased that the IFT jury recognized that.” reFRESH™ couples ... a natural way to extend the shelf life and improve the safety of perishable ...
(Date:7/10/2020)... ... July 09, 2020 , ... In most research ... to suppress pigment formation in zebrafish embryos, maintaining optical transparency to facilitate microscopic ... MA has been using the zebrafish model to investigate the causes of leukaemia ...
Breaking Biology Technology: